<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266708</url>
  </required_header>
  <id_info>
    <org_study_id>02-08-224</org_study_id>
    <nct_id>NCT00266708</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.</brief_title>
  <official_title>Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with kidney failure have underlying bone disease at the time of transplant.
      Fractures of various bones can be as high as 22%. Medication required for the transplant
      plays a role in bone loss.

      Bisphosphonates are used in the general population to treat bone loss of osteoporosis and
      steroid-induced bone loss. While previous studies, using various bisphosphonates, have shown
      preservation of bone mineral density in renal transplant recipients, we have demonstrated
      that pamidronate, a second generation bisphosphonate, is associated with low bone turnover
      while still preserving bone mineral density. Improved bone mineral density is associated with
      decreased fracture risk in the general population, while low bone turnover may be associated
      with increased fracture in dialysis patients.

      The purpose of this study is to determine whether risedronate, a third generation
      bisphosphonate, is effective in preserving bone density when given prophylactically following
      renal transplantation and whether it is associated with low bone turnover at one year
      following renal transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who receive a living donor kidney transplant undergo a bone biopsy at the time
      of kidney transplant and after one year of protocol. Once adequate kidney function is
      established, both groups take by mouth a weekly capsule (the control group has a placebo; the
      treatment group has risedronate 35 mg). Both groups undergo baseline, 6 month and 12 month
      dual energy x-ray absorptiometry (DEXA) bone mineral density scans. Both groups undergo bone
      hormonal studies at regular intervals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density of Spine at 6 Months</measure>
    <time_frame>month 6 of the treatment</time_frame>
    <description>Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using the Hologic 4500 QDC scanner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density of Spine at 12 Months</measure>
    <time_frame>month 12 of treatment</time_frame>
    <description>Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using same Hologic 4500 QDC scanner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density of the Hip at 6 Months</measure>
    <time_frame>month 6 of the treatment</time_frame>
    <description>Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density of the Hip at 12 Months</measure>
    <time_frame>month 12 of the treatment</time_frame>
    <description>Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density of Forearm at 6 Months</measure>
    <time_frame>month 6 of the treatment</time_frame>
    <description>Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density of Forearm at 12 Months</measure>
    <time_frame>month 12 of the treatment</time_frame>
    <description>Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Percent Bone Volume (BV/TV)</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Percent Bone Volume is the percentage of total volume occupied by calcified bone. Percent Bone volume is calculated as Bone Volume (BV) divided by Tissue Volume (TV), where TV is bone plus marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Trabecular Thickness (TbTh)</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. The ends of certain bones, known as cancellous bones, are actually not solid but are full of holes that are connected to each other by thin rods and plates of bone tissue known as trabeculae. Trabeculae of bone provide structural support to the spongy bone found at the ends of long bones. Trabeculae Trabecular Thickness (TbTh), a structural parameter, is the distance across individual trabecula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Percent Mineralized Bone Volume (MdV/BV)</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Percent Mineralized Bone Volume is the percentage of Bone Volume consisting of mineralized bone. Percent Mineralized Bone Volume is calculated as Mineralized Bone Volume (MdV) divided by Bone Volume (BV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Mineralized Bone Volume (MdV)</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Bone mineralization is the process of laying down minerals on the matrix of the bone, with calcium and phosphorus as the most abundant minerals. Mineralized Bone Volume (MdV) is the percentage of mineralized bone tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Percent Osteoid Volume Relative to Bone Volume(OV/BV)</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of a given volume of bone that consists of unmineralized bone. It is equal to Osteoid Volume (OV) divided by Bone Volume (BV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Percent Osteoid Volume Relative to Tissue Volume (OV/TV)</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of a given volume of tissue (bone + marrow) that consists of unmineralized bone. It is equal to Osteoid Volume (OV) divided by Tissue Volume (TV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Percent Osteoid Surface Relative to Bone Surface (OS/BS)</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of bone surface that consists of unmineralized bone. It is equal to Osteoid Surface (OS) divided by Bone Surface (BS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Percent Osteoblasts Relative to Bone Surface (OB/BS)</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized. Bone mass is a balance between the osteoblasts (OB) that form the bone and cells called osteoclasts (OC) that break down the bone. The reported values indicate the percent of bone surface (BS) that is made up of osteoblasts (OB).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Percent Osteoclasts Relative to Bone Surface (OC/BS)</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones. Osteoclasts make and secrete digestive enzymes that break up or dissolve the bone tissue. Bone mass is a balance between the osteoblasts (OB) cells that form the bone and the osteoclasts (OC) cells that break down the bone. The reported values indicate the percent of bone surface (BS) that consists of osteoclasts (OC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Percent Eroded Surface Relative to Bone Surface (ES/BS)</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones. Osteoclasts make and secret digestive enzymes tha break up or dissolve the bone tissue. An eroded surface (ES) is the surface of the lacuna ( a cavity or depression in the bone) generated by an active OC. The reported values indicate the percent of eroded surface relative to bone surface (BS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Bone Formation Rate</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized. Bone formation rate (BFR) indicates how much of the bone is actively mineralizing; it is determined by the number of active OB and the average work of each OB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry - Osteoid Volume (OV)</measure>
    <time_frame>Baseline and month 12 of the treatment</time_frame>
    <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the Osteoid Volume (OV), the volume of bone that consists of unmineralized bone.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Renal Transplant Osteodystrophy</condition>
  <arm_group>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received Risedronate for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subjects received placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects received placebo for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <description>risedronate 35 mg weekly</description>
    <arm_group_label>Risedronate</arm_group_label>
    <other_name>bisphosphonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Risedronate Placebo 35 mg weekly</description>
    <arm_group_label>subjects received placebo</arm_group_label>
    <other_name>Risedronate placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with end stage renal disease who are undergoing living donor kidney
             transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Coco, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Coco M, Pullman J, Cohen HW, Lee S, Shapiro C, Solorzano C, Greenstein S, Glicklich D. Effect of risedronate on bone in renal transplant recipients. J Am Soc Nephrol. 2012 Aug;23(8):1426-37. doi: 10.1681/ASN.2011060623. Epub 2012 Jul 12.</citation>
    <PMID>22797188</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 15, 2005</study_first_submitted>
  <study_first_submitted_qc>December 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2005</study_first_posted>
  <results_first_submitted>February 5, 2019</results_first_submitted>
  <results_first_submitted_qc>February 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2019</results_first_posted>
  <last_update_submitted>February 5, 2019</last_update_submitted>
  <last_update_submitted_qc>February 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal transplant</keyword>
  <keyword>post-transplant osteoporosis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronic Acid</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Transplant candidates from Montefiore Medical Centre were recruited for the study.</recruitment_details>
      <pre_assignment_details>117 transplant candidates were identified as potentially eligible for the study. 57 of the 117 refused to participate and 60 of the candidates signed consent forms. Of the 60 who signed, 18 were either not transplanted or lost to follow-up so only 42 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Risedronate</title>
          <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>subjects received placebo for 1 year
Placebo weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No renal function</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused biopsy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Asthma</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Risedronate</title>
          <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>subjects received placebo for 1 year
Placebo weekly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="11"/>
                    <measurement group_id="B2" value="48" spread="14"/>
                    <measurement group_id="B3" value="44.7" spread="12.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMD Calcium - Spine</title>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.01" spread="0.17"/>
                    <measurement group_id="B2" value="1.01" spread="0.17"/>
                    <measurement group_id="B3" value="1.01" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMD Calcium - Hip</title>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.90" spread="0.15"/>
                    <measurement group_id="B2" value="0.92" spread="0.17"/>
                    <measurement group_id="B3" value="0.909" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMD Calcium - Forearm</title>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.54" spread="0.09"/>
                    <measurement group_id="B2" value="0.61" spread="0.09"/>
                    <measurement group_id="B3" value="0.57" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density of Spine at 6 Months</title>
        <description>Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using the Hologic 4500 QDC scanner.</description>
        <time_frame>month 6 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density of Spine at 6 Months</title>
          <description>Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using the Hologic 4500 QDC scanner.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.16"/>
                    <measurement group_id="O2" value="0.97" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density of Spine at 12 Months</title>
        <description>Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using same Hologic 4500 QDC scanner.</description>
        <time_frame>month 12 of treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density of Spine at 12 Months</title>
          <description>Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using same Hologic 4500 QDC scanner.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.18"/>
                    <measurement group_id="O2" value="1.00" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density of the Hip at 6 Months</title>
        <description>Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner.</description>
        <time_frame>month 6 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density of the Hip at 6 Months</title>
          <description>Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.13"/>
                    <measurement group_id="O2" value="0.86" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density of the Hip at 12 Months</title>
        <description>Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner.</description>
        <time_frame>month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density of the Hip at 12 Months</title>
          <description>Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.13"/>
                    <measurement group_id="O2" value="0.87" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density of Forearm at 6 Months</title>
        <description>Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner.</description>
        <time_frame>month 6 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density of Forearm at 6 Months</title>
          <description>Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.11"/>
                    <measurement group_id="O2" value="0.58" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density of Forearm at 12 Months</title>
        <description>Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner.</description>
        <time_frame>month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density of Forearm at 12 Months</title>
          <description>Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.12"/>
                    <measurement group_id="O2" value="0.58" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Percent Bone Volume (BV/TV)</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Percent Bone Volume is the percentage of total volume occupied by calcified bone. Percent Bone volume is calculated as Bone Volume (BV) divided by Tissue Volume (TV), where TV is bone plus marrow.</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Percent Bone Volume (BV/TV)</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Percent Bone Volume is the percentage of total volume occupied by calcified bone. Percent Bone volume is calculated as Bone Volume (BV) divided by Tissue Volume (TV), where TV is bone plus marrow.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="6"/>
                    <measurement group_id="O2" value="13.3" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="5"/>
                    <measurement group_id="O2" value="9.7" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Trabecular Thickness (TbTh)</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. The ends of certain bones, known as cancellous bones, are actually not solid but are full of holes that are connected to each other by thin rods and plates of bone tissue known as trabeculae. Trabeculae of bone provide structural support to the spongy bone found at the ends of long bones. Trabeculae Trabecular Thickness (TbTh), a structural parameter, is the distance across individual trabecula.</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Trabecular Thickness (TbTh)</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. The ends of certain bones, known as cancellous bones, are actually not solid but are full of holes that are connected to each other by thin rods and plates of bone tissue known as trabeculae. Trabeculae of bone provide structural support to the spongy bone found at the ends of long bones. Trabeculae Trabecular Thickness (TbTh), a structural parameter, is the distance across individual trabecula.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>micron</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" spread="17"/>
                    <measurement group_id="O2" value="90.9" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="28"/>
                    <measurement group_id="O2" value="62.2" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Percent Mineralized Bone Volume (MdV/BV)</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Percent Mineralized Bone Volume is the percentage of Bone Volume consisting of mineralized bone. Percent Mineralized Bone Volume is calculated as Mineralized Bone Volume (MdV) divided by Bone Volume (BV).</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Percent Mineralized Bone Volume (MdV/BV)</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Percent Mineralized Bone Volume is the percentage of Bone Volume consisting of mineralized bone. Percent Mineralized Bone Volume is calculated as Mineralized Bone Volume (MdV) divided by Bone Volume (BV).</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" spread="3"/>
                    <measurement group_id="O2" value="95" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" spread="7"/>
                    <measurement group_id="O2" value="96" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Mineralized Bone Volume (MdV)</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Bone mineralization is the process of laying down minerals on the matrix of the bone, with calcium and phosphorus as the most abundant minerals. Mineralized Bone Volume (MdV) is the percentage of mineralized bone tissue.</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Mineralized Bone Volume (MdV)</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Bone mineralization is the process of laying down minerals on the matrix of the bone, with calcium and phosphorus as the most abundant minerals. Mineralized Bone Volume (MdV) is the percentage of mineralized bone tissue.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.4"/>
                    <measurement group_id="O2" value="1.3" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.5"/>
                    <measurement group_id="O2" value="1.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Percent Osteoid Volume Relative to Bone Volume(OV/BV)</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of a given volume of bone that consists of unmineralized bone. It is equal to Osteoid Volume (OV) divided by Bone Volume (BV).</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Percent Osteoid Volume Relative to Bone Volume(OV/BV)</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of a given volume of bone that consists of unmineralized bone. It is equal to Osteoid Volume (OV) divided by Bone Volume (BV).</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.6"/>
                    <measurement group_id="O2" value="4.6" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="7.2"/>
                    <measurement group_id="O2" value="4.9" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Percent Osteoid Volume Relative to Tissue Volume (OV/TV)</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of a given volume of tissue (bone + marrow) that consists of unmineralized bone. It is equal to Osteoid Volume (OV) divided by Tissue Volume (TV).</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Percent Osteoid Volume Relative to Tissue Volume (OV/TV)</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of a given volume of tissue (bone + marrow) that consists of unmineralized bone. It is equal to Osteoid Volume (OV) divided by Tissue Volume (TV).</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.4"/>
                    <measurement group_id="O2" value="0.58" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.8"/>
                    <measurement group_id="O2" value="0.51" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Percent Osteoid Surface Relative to Bone Surface (OS/BS)</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of bone surface that consists of unmineralized bone. It is equal to Osteoid Surface (OS) divided by Bone Surface (BS).</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Percent Osteoid Surface Relative to Bone Surface (OS/BS)</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of bone surface that consists of unmineralized bone. It is equal to Osteoid Surface (OS) divided by Bone Surface (BS).</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="18"/>
                    <measurement group_id="O2" value="15" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="27"/>
                    <measurement group_id="O2" value="14" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Percent Osteoblasts Relative to Bone Surface (OB/BS)</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized. Bone mass is a balance between the osteoblasts (OB) that form the bone and cells called osteoclasts (OC) that break down the bone. The reported values indicate the percent of bone surface (BS) that is made up of osteoblasts (OB).</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Percent Osteoblasts Relative to Bone Surface (OB/BS)</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized. Bone mass is a balance between the osteoblasts (OB) that form the bone and cells called osteoclasts (OC) that break down the bone. The reported values indicate the percent of bone surface (BS) that is made up of osteoblasts (OB).</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3"/>
                    <measurement group_id="O2" value="1.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="1.6"/>
                    <measurement group_id="O2" value="0.75" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Percent Osteoclasts Relative to Bone Surface (OC/BS)</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones. Osteoclasts make and secrete digestive enzymes that break up or dissolve the bone tissue. Bone mass is a balance between the osteoblasts (OB) cells that form the bone and the osteoclasts (OC) cells that break down the bone. The reported values indicate the percent of bone surface (BS) that consists of osteoclasts (OC).</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Percent Osteoclasts Relative to Bone Surface (OC/BS)</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones. Osteoclasts make and secrete digestive enzymes that break up or dissolve the bone tissue. Bone mass is a balance between the osteoblasts (OB) cells that form the bone and the osteoclasts (OC) cells that break down the bone. The reported values indicate the percent of bone surface (BS) that consists of osteoclasts (OC).</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.9"/>
                    <measurement group_id="O2" value="0.97" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.43"/>
                    <measurement group_id="O2" value="0.68" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Percent Eroded Surface Relative to Bone Surface (ES/BS)</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones. Osteoclasts make and secret digestive enzymes tha break up or dissolve the bone tissue. An eroded surface (ES) is the surface of the lacuna ( a cavity or depression in the bone) generated by an active OC. The reported values indicate the percent of eroded surface relative to bone surface (BS).</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Percent Eroded Surface Relative to Bone Surface (ES/BS)</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones. Osteoclasts make and secret digestive enzymes tha break up or dissolve the bone tissue. An eroded surface (ES) is the surface of the lacuna ( a cavity or depression in the bone) generated by an active OC. The reported values indicate the percent of eroded surface relative to bone surface (BS).</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="11"/>
                    <measurement group_id="O2" value="1.36" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3"/>
                    <measurement group_id="O2" value="0.82" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Bone Formation Rate</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized. Bone formation rate (BFR) indicates how much of the bone is actively mineralizing; it is determined by the number of active OB and the average work of each OB.</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Bone Formation Rate</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized. Bone formation rate (BFR) indicates how much of the bone is actively mineralizing; it is determined by the number of active OB and the average work of each OB.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>micron/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.05"/>
                    <measurement group_id="O2" value="0.04" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.16"/>
                    <measurement group_id="O2" value="0.05" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry - Osteoid Volume (OV)</title>
        <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the Osteoid Volume (OV), the volume of bone that consists of unmineralized bone.</description>
        <time_frame>Baseline and month 12 of the treatment</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects received placebo for 1 year
Placebo weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry - Osteoid Volume (OV)</title>
          <description>Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the Osteoid Volume (OV), the volume of bone that consists of unmineralized bone.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>micron^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.04"/>
                    <measurement group_id="O2" value="0.06" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.09"/>
                    <measurement group_id="O2" value="0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected during course of study, which lasted 6 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Risedronate</title>
          <description>subjects received Risedronate for one year
Risedronate 35 Mg: risedronate 35 mg weekly</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>subjects received placebo for 1 year
Placebo weekly</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep venous thrombosis</sub_title>
                <description>venous thrombosis and Blood clots that develop in a vein, usually in the leg or thing. It can cause pain and swelling in the leg and may lead to complications such as pulmonary embolism.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria Coco, MD</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-920-4136</phone>
      <email>mcoco@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

